PDCD1 and neoplasm: Although anti-PD-1/PD-L1 therapy has demonstrated remarkable anti-tumor effects in multiple cancer types, only 10–40% patients show clinical response by monotherapy, and thus, there is an urgent need to develop new ICB therapy as well as predictive biomarkers to improve therapeutic efficacy [29–31].